| Drug Type Synthetic peptide | 
| Synonyms CHM 273, CHM273 | 
| Target | 
| Action modulators | 
| Mechanism FFAR2 modulators(Free fatty acid receptor 2 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Metabolic Diseases | Preclinical | United States  | - | |
| Diabetes Mellitus, Type 2 | Discovery | United States  | 01 Dec 2024 | |
| Diabetic Nephropathies | Discovery | United States  | 01 Dec 2024 | |
| Well Aging | Discovery | United States  | 01 Dec 2024 | 






